Valneva: application filed for chikungunya vaccine in Canada
(CercleFinance.com) - Valneva announces the submission, to Health Canada, of a marketing authorization application (MAA) for its single-injection chikungunya vaccine candidate, VLA1553, for people aged 18 and over.
This is the second regulatory application for VLA1553 filed by the company, which intends to file more in 2023, including in Europe. A marketing authorization application is currently under priority review by the US FDA.
VLA1553 is currently the only chikungunya vaccine candidate in the world for which a regulatory review process is underway. It could thus become the first vaccine to address this unmet medical need.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
This is the second regulatory application for VLA1553 filed by the company, which intends to file more in 2023, including in Europe. A marketing authorization application is currently under priority review by the US FDA.
VLA1553 is currently the only chikungunya vaccine candidate in the world for which a regulatory review process is underway. It could thus become the first vaccine to address this unmet medical need.
Copyright (c) 2023 CercleFinance.com. All rights reserved.